Theramex (PRIVATE.THERAMEX)

Overall impact
C (48)

Commentary

Theramex is an average overall performer. With a 'C' rating of 48.1 for overall impact (37th percentile compared to all companies), Theramex ranks 136th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 132 others, and ahead of Tilray, Organon, OSR Biosciences and 15 others. On top material causes for Theramex's industry (Pharmaceuticals & Biotech), Theramex performs well in Access to Affordable Healthcare (82.1 score), Technology Innovation (95.1), Child and Maternal Health (95.4) and 1 other cause where it received an 'A' score and performs poorly in Improved Mental Health (36.9 score), Equal Pay and Opportunity (36.5), Reduced Use of tobacco (27.7) and 8 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.THERAMEX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1954
Employees
500
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
England, United Kingdom
Share classes
PRIVATE.THERAMEX
Description
Manufacturer of drugs and medicines catering to the health and well-being of women. The company's product portfolio offers a wide range of prescription products in the clinical areas of contraception, fertility, menopause and osteoporosis, delivering patient-focused solutions that care for and support women as they advance through each stage of their lives.
Material causes
Ethos considers the following causes material for Theramex, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.